Cancer
Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
Published in Cancer Weekly, July 7th, 2009
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) reported the issuance of a U.S. patent with broad claims covering vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent represents the first broad coverage of imaging claims under Peregrine's PS-targeting platform, which includes Peregrine's lead antibody bavituximab. PS is a phospholipid that becomes exposed on the surface of tumor blood vessel cells. Since PS is typically not exposed on the surface of normal tissues, it represents a unique target for the vascular imaging of tumors and tumor metastases in patients with cancer.
"PS-targeting antibodies such as bavituximab preferentially...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-07-07)
More Articles from Cancer Weekly
- American Association for Cancer Research
Green tea may affect prostate cancer progression - World Journal of Gastroenterology
Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells - BloodCenter of Wisconsin
BloodCenter of Wisconsin’s New Genetic Test Identifies People at High Risk for Developing Inherited Form of Leukemia - Breast Cancer
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations - Breast Cancer
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer - Cancer Vaccines
Data from Vrije University Amsterdam provide new insights into cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
